These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 7994589)

  • 1. Preselection of patients with high TAG-72 antigen expression leads to targeting of 94% of known metastatic tumor sites with monoclonal antibody I-131-CC49.
    Kostakoglu L; Divgi CR; Hilton S; Cordon-Cardo C; Scott AM; Kalaigian H; Finn RD; Schlom J; Larson SM
    Cancer Invest; 1994; 12(6):551-8. PubMed ID: 7994589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma.
    Divgi CR; Scott AM; Dantis L; Capitelli P; Siler K; Hilton S; Finn RD; Kemeny N; Kelsen D; Kostakoglu L
    J Nucl Med; 1995 Apr; 36(4):586-92. PubMed ID: 7699446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical comparison of radiolocalization of two monoclonal antibodies (mAbs) against the TAG-72 antigen.
    Divgi CR; Scott AM; McDermott K; Fallone PS; Hilton S; Siler K; Carmichael N; Daghighian F; Finn RD; Cohen AM
    Nucl Med Biol; 1994 Jan; 21(1):9-15. PubMed ID: 9234259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
    Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
    Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
    Macey DJ; Grant EJ; Kasi L; Rosenblum MG; Zhang HZ; Katz RL; Rieger PT; LeBherz D; South M; Greiner JW; Schlom J; Podoloff DA; Murray JL
    Clin Cancer Res; 1997 Sep; 3(9):1547-55. PubMed ID: 9815842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts.
    Welt S; Divgi CR; Scott AM; Garin-Chesa P; Finn RD; Graham M; Carswell EA; Cohen A; Larson SM; Old LJ
    J Clin Oncol; 1994 Jun; 12(6):1193-203. PubMed ID: 8201382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer.
    Murray JL; Macey DJ; Kasi LP; Rieger P; Cunningham J; Bhadkamkar V; Zhang HZ; Schlom J; Rosenblum MG; Podoloff DA
    Cancer; 1994 Feb; 73(3 Suppl):1057-66. PubMed ID: 8306248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
    Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
    Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraoperative detection of occult colon cancer micrometastases using 125 I-radiolabled monoclonal antibody CC49.
    Cote RJ; Houchens DP; Hitchcock CL; Saad AD; Nines RG; Greenson JK; Schneebaum S; Arnold MW; Martin EW
    Cancer; 1996 Feb; 77(4):613-20. PubMed ID: 8616751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical validation of SPECT and CT/MRI image registration in radiolabeled monoclonal antibody studies of colorectal carcinoma.
    Scott AM; Macapinlac HA; Divgi CR; Zhang JJ; Kalaigian H; Pentlow K; Hilton S; Graham MC; Sgouros G; Pelizzari C
    J Nucl Med; 1994 Dec; 35(12):1976-84. PubMed ID: 7989980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
    J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer.
    Slovin SF; Scher HI; Divgi CR; Reuter V; Sgouros G; Moore M; Weingard K; Pettengall R; Imbriaco M; El-Shirbiny A; Finn R; Bronstein J; Brett C; Milenic D; Dnistrian A; Shapiro L; Schlom J; Larson SM
    Clin Cancer Res; 1998 Mar; 4(3):643-51. PubMed ID: 9533532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of immunoscintigraphy using a cocktail of radiolabeled monoclonal antibodies in the detection of colorectal cancer.
    Volpe CM; Abdel-Nabi HH; Kulaylat MN; Doerr RJ
    Ann Surg Oncol; 1998 Sep; 5(6):489-94. PubMed ID: 9754756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (131I-CC49) when given in combination with gamma-interferon.
    Greiner JW; Ullmann CD; Nieroda C; Qi CF; Eggensperger D; Shimada S; Steinberg SM; Schlom J
    Cancer Res; 1993 Feb; 53(3):600-8. PubMed ID: 8425194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.
    Pavlinkova G; Booth BJ; Batra SK; Colcher D
    Clin Cancer Res; 1999 Sep; 5(9):2613-9. PubMed ID: 10499640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot radioimmunotherapy trial with 131I-labeled murine monoclonal antibody CC49 and deoxyspergualin in metastatic colon carcinoma.
    Divgi CR; Scott AM; Gulec S; Broussard EK; Levy N; Young C; Capitelli P; Daghighian F; Williams JM; Finn RD
    Clin Cancer Res; 1995 Dec; 1(12):1503-10. PubMed ID: 9815950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study evaluating the intraoperative localization of radiolabeled monoclonal antibody CC83 in patients with metastatic colorectal carcinoma.
    Burak WE; Schneebaum S; Kim JA; Arnold MW; Hinkle G; Berens A; Mojzisik C; Martin EW
    Surgery; 1995 Jul; 118(1):103-8. PubMed ID: 7604370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha-interferon treatment.
    Murray JL; Macey DJ; Grant EJ; Rosenblum MG; Kasi LP; Zhang HZ; Katz RL; Riger PT; LeBherz D; Bhadkamkar V
    Cancer Res; 1995 Dec; 55(23 Suppl):5925s-5928s. PubMed ID: 7493372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lesion-by-lesion comparison of computerized tomography and indium-111-labeled monoclonal antibody C110 radioimmunoscintigraphy in colorectal carcinoma: a multicenter trial.
    Divgi CR; McDermott K; Griffin TW; Johnson DK; Schnobrich KE; Fallone PS; Scott AM; Hilton S; Cohen AM; Larson SM
    J Nucl Med; 1993 Oct; 34(10):1656-61. PubMed ID: 8410278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.